Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Debt: 2023-2024

Historic Total Debt for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Dec 2024 value amounting to $7.5 million.

  • Tonix Pharmaceuticals Holding's Total Debt fell 15.98% to $7.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.5 million, marking a year-over-year decrease of 15.98%. This contributed to the annual value of $7.5 million for FY2024, which is 15.98% down from last year.
  • According to the latest figures from Q4 2024, Tonix Pharmaceuticals Holding's Total Debt is $7.5 million, which was down 6.32% from $8.0 million recorded in Q3 2024.
  • Tonix Pharmaceuticals Holding's Total Debt's 5-year high stood at $9.0 million during Q1 2024, with a 5-year trough of $7.5 million in Q4 2024.
  • Its 2-year average for Total Debt is $8.4 million, with a median of $8.5 million in 2024.
  • Data for Tonix Pharmaceuticals Holding's Total Debt shows a maximum YoY dropped of 15.98% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Total Debt (Quarterly) stood at $8.9 million in 2023, then decreased by 15.98% to $7.5 million in 2024.
  • Its Total Debt was $7.5 million in Q4 2024, compared to $8.0 million in Q3 2024 and $8.5 million in Q2 2024.